Schroder Investment Management Group Lowers Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Schroder Investment Management Group decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 72.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,000 shares of the company's stock after selling 61,999 shares during the period. Schroder Investment Management Group's holdings in Intellia Therapeutics were worth $274,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in NTLA. Franklin Resources Inc. increased its holdings in Intellia Therapeutics by 10.3% during the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company's stock worth $320,000 after purchasing an additional 1,538 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in shares of Intellia Therapeutics by 14.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company's stock valued at $157,000 after acquiring an additional 1,582 shares in the last quarter. Arizona State Retirement System lifted its stake in Intellia Therapeutics by 6.1% in the fourth quarter. Arizona State Retirement System now owns 28,006 shares of the company's stock worth $327,000 after acquiring an additional 1,615 shares during the period. E Fund Management Co. Ltd. grew its holdings in Intellia Therapeutics by 10.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company's stock worth $210,000 after acquiring an additional 1,634 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in Intellia Therapeutics by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,596 shares of the company's stock valued at $252,000 after purchasing an additional 2,059 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Stock Up 2.0 %

Shares of Intellia Therapeutics stock traded up $0.15 on Monday, reaching $7.56. 319,690 shares of the stock were exchanged, compared to its average volume of 3,404,325. The business has a 50 day moving average price of $9.15 and a two-hundred day moving average price of $12.53. The firm has a market capitalization of $782.38 million, a price-to-earnings ratio of -1.38 and a beta of 2.23. Intellia Therapeutics, Inc. has a twelve month low of $5.90 and a twelve month high of $28.18.

Wall Street Analyst Weigh In

NTLA has been the topic of a number of recent research reports. Wedbush reiterated a "neutral" rating and set a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Morgan Stanley downgraded Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $56.00 to $11.00 in a report on Monday, January 27th. Citigroup upped their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a "neutral" rating in a research note on Friday, February 28th. Barclays cut their target price on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and set a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Intellia Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.56.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.